Insmed Incorporated (NASDAQ:INSM) Insider Sells $138,106.50 in Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) insider Michael Alexander Smith sold 1,879 shares of Insmed stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $73.50, for a total transaction of $138,106.50. Following the completion of the sale, the insider now owns 67,718 shares in the company, valued at $4,977,273. The trade was a 2.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Michael Alexander Smith also recently made the following trade(s):

• On Tuesday, June 3rd, Michael Alexander Smith sold 1,448 shares of Insmed stock. The stock was sold at an average price of $71.50, for a total transaction of $103,532.00.
• On Wednesday, May 14th, Michael Alexander Smith sold 409 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total value of $26,834.49.
• On Tuesday, May 13th, Michael Alexander Smith sold 4,407 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total value of $298,838.67.

Insmed Stock Performance

Shares of NASDAQ INSM traded up $0.88 during trading hours on Friday, reaching $73.62. 1,558,246 shares of the stock were exchanged, compared to its average volume of 2,074,730. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market capitalization of $13.41 billion, a price-to-earnings ratio of -13.17 and a beta of 0.80. The stock's fifty day simple moving average is $69.25 and its 200 day simple moving average is $73.03. Insmed Incorporated has a 52 week low of $55.74 and a 52 week high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. During the same period in the previous year, the firm posted ($1.06) EPS. The company's revenue was up 22.9% compared to the same quarter last year. Sell-side analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on INSM shares. HC Wainwright reiterated a "buy" rating and set a $90.00 price objective on shares of Insmed in a research note on Monday, May 12th. UBS Group lowered their target price on shares of Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Wells Fargo & Company increased their price target on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. Truist Financial boosted their price objective on shares of Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Finally, Morgan Stanley raised their target price on shares of Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $96.73.

Institutional Investors Weigh In On Insmed

Large investors have recently added to or reduced their stakes in the stock. National Bank of Canada FI raised its holdings in Insmed by 9.7% in the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock valued at $115,000 after acquiring an additional 147 shares in the last quarter. M&T Bank Corp increased its position in shares of Insmed by 4.7% in the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after purchasing an additional 147 shares during the period. Snowden Capital Advisors LLC raised its stake in Insmed by 2.5% in the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock valued at $456,000 after purchasing an additional 158 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its position in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Insmed by 3.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company's stock worth $446,000 after purchasing an additional 186 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.